Alaunos Therapeutics Inc (TCRT)
2.39
+0.07
(+3.02%)
USD |
NASDAQ |
Nov 22, 16:00
2.355
-0.04
(-1.46%)
After-Hours: 20:00
Alaunos Therapeutics Cash from Financing (Quarterly): 0.00 for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | -11.98M |
| March 31, 2023 | -6.158M |
| December 31, 2022 | 8.474M |
| September 30, 2022 | -2.107M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -0.186M |
| September 30, 2021 | 24.93M |
| June 30, 2021 | 0.019M |
| March 31, 2021 | 1.017M |
| December 31, 2020 | 0.40M |
| September 30, 2020 | 0.027M |
| June 30, 2020 | 0.012M |
| March 31, 2020 | 101.68M |
| December 31, 2019 | 3.03M |
| September 30, 2019 | 55.89M |
| June 30, 2019 | 0.23M |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 41.35M |
| September 30, 2018 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2018 | -0.304M |
| March 31, 2018 | -0.731M |
| December 31, 2017 | -1.028M |
| September 30, 2017 | 0.001M |
| June 30, 2017 | 46.30M |
| March 31, 2017 | 0.029M |
| December 31, 2016 | -0.484M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | -0.669M |
| March 31, 2016 | 0.365M |
| December 31, 2015 | 1.063M |
| September 30, 2015 | 0.093M |
| June 30, 2015 | 0.565M |
| March 31, 2015 | 96.62M |
| December 31, 2014 | 6.551M |
| September 30, 2014 | 3.706M |
| June 30, 2014 | 0.348M |
| March 31, 2014 | 0.837M |
| December 31, 2013 | 53.63M |
| September 30, 2013 | 0.202M |
| June 30, 2013 | -0.001M |
| March 31, 2013 | 0.706M |
| December 31, 2012 | -0.45M |
| September 30, 2012 | 0.024M |
| June 30, 2012 | 0.101M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.98M
Minimum
Jun 2023
101.68M
Maximum
Mar 2020
5.958M
Average
--
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Microbot Medical Inc | 0.633M |
| SELLAS Life Sciences Group Inc | 19.69M |
| Galectin Therapeutics Inc | 10.00M |
| Oragenics Inc | 3.766M |
| Anavex Life Sciences Corp | 4.55M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.781M |
| Free Cash Flow | -11.76M |
| Free Cash Flow Per Share (Quarterly) | -0.4877 |
| Free Cash Flow Yield | -307.4% |